Belite Bio, Inc. ADR (BLTE)
NASDAQ:BLTE
Want to see BLTE full AI Analyst Report?
Top Page
Belite Bio, Inc. ADR
(NASDAQ:BLTE)
Select Model
Select Model
Rating:57Neutral
Price Target:
$140.00
▼(-15.38% Downside)
Action:Reiterated
Date:06/03/26
BLTE’s score is held back primarily by weak current financial performance (no revenue, widening losses, and ongoing cash burn), with additional pressure from bearish technicals. These are partly offset by a very strong balance sheet and a constructive earnings update highlighting NDA progress, clinical execution milestones, and substantial cash runway.
Positive Factors
Strong Balance Sheet
A very strong balance sheet with minimal debt and a large equity base provides durable financial flexibility to fund late‑stage development, the NDA process, and initial commercialization without immediate reliance on dilutive financing, supporting multi‑quarter execution risk.
Negative Factors
Widening Cash Burn
Sustained and accelerating negative operating cash flow is a durable structural headwind: it increases dependency on existing cash reserves or future financing, reduces optionality for strategic moves, and heightens exposure to funding risk if development timelines or costs inflate.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Balance Sheet
A very strong balance sheet with minimal debt and a large equity base provides durable financial flexibility to fund late‑stage development, the NDA process, and initial commercialization without immediate reliance on dilutive financing, supporting multi‑quarter execution risk.
Read all positive factors
Belite Bio, Inc. ADR (BLTE) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$5.79B
Dividend YieldN/A
Average Volume (3M)64.23K
Price to Earnings (P/E)―
Beta (1Y)0.77
Revenue GrowthN/A
EPS Growth-85.65%
CountryUS
Employees25
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.66
Shares Outstanding39,965,313
10 Day Avg. Volume75,810
30 Day Avg. Volume64,229
Financial Highlights & Ratios
PEG Ratio-0.72
Price to Book (P/B)6.96
Price to Sales (P/S)0.00
P/FCF Ratio-144.35
Enterprise Value/Market Cap0.94
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-86.81
Forecast
1Y Price Target
$220.25Price Target Upside33.12% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-3.21
Revenue Forecast (FY)$22.50M
Belite Bio, Inc. ADR Business Overview & Revenue Model
Company Description
Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead pr...
How the Company Makes Money
As a clinical-stage biopharmaceutical company, Belite Bio has not established a mature commercial product portfolio; accordingly, publicly available information does not indicate recurring product sales as a primary revenue source. Typical monetiz...
Belite Bio, Inc. ADR Earnings Call Summary
Earnings Call Date:May 20, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 12, 2026
Earnings Call Sentiment Positive
The call conveyed strong program and commercial progress—Phase 3 report received, NDA rolling submission underway, Dragon 2 enrollment completed, substantial commercial hires, and a robust cash position (~$799M). However, the company is incurring sharply higher R&D and SG&A expenses, net losses widened materially, and several clinical and regulatory uncertainties remain (GA interim unknown; FDA guidance requires completion of Dragon 1 at 2 years). On balance the positive development and financial runway outweigh the near‑term expense and uncertainty headwinds.Positive Updates
Phase 3 Milestone and NDA Rolling Submission
Received the Phase 3 clinical study report in Q1 2026 without delay and initiated an NDA rolling submission to the FDA in April; company is on track to complete the submission by Q2 2026.
Negative Updates
Sharp Increases in R&D Spending
Q1 2026 R&D expenses were $15.7M vs. $9.4M in Q1 2025, an increase of $6.3M (~67.0%). On a non‑GAAP basis excluding share‑based comp, R&D rose to $13.8M from $7.4M, an increase of $6.4M (~86.5%). Drivers include Dragon 2 trial costs, API/drug product manufacturing, and higher consulting/professional fees.
Read all updates
Q1-2026 Updates
Positive
Negative
Phase 3 Milestone and NDA Rolling Submission
Received the Phase 3 clinical study report in Q1 2026 without delay and initiated an NDA rolling submission to the FDA in April; company is on track to complete the submission by Q2 2026.
Read all positive updates
Company Guidance
Management guided that they received the Phase 3 study report in Q1 2026 and initiated an NDA rolling submission in April expected to be completed by Q2 2026, followed by a standard ~6‑month FDA review (approval as early as 2027 was discussed) with PMDA Sakigake potentially granting approval within ~3 months of FDA; they completed enrollment in the Phase 2/3 Dragon 2 study (73 subjects, ages 12–20, in Japan/U.S./UK), noted FDA recommended completing Dragon 2 to 2 years with a possible single‑study approval based on data robustness, and are targeting a GA interim readout around year‑end. Financial and commercial metrics: Q1 2026 R&D $15.7M (non‑GAAP excl. SBC $13.8M) vs Q1 2025 $9.4M/$7.4M, SG&A $17.0M (non‑GAAP $5.7M) vs $6.1M/$1.5M, GAAP net loss $26.9M (non‑GAAP net loss $13.7M) vs $14.3M/$7.6M, cash and U.S. T‑bills $799M, headcount ramped ~30→~90, planned commercial team ~30–40, estimated U.S. launch funding ~ $300M with ~$150M for the pipeline over 3 years (total ~ $450M), and a preliminary pricing reference range of ~$350k–$500k.Belite Bio, Inc. ADR Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
86
Very Positive
Cash Flow
32
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | -198.00K | -30.00K |
| EBITDA | -84.21M | -35.67M | -31.20M | -12.43M | -9.64M |
| Net Income | -77.61M | -36.14M | -31.63M | -12.65M | -9.67M |
Balance Sheet | |||||
| Total Assets | 780.56M | 152.13M | 94.64M | 44.27M | 18.35M |
| Cash, Cash Equivalents and Short-Term Investments | 492.42M | 145.15M | 88.16M | 42.09M | 17.34M |
| Total Debt | 429.00K | 537.00K | 886.00K | 866.00K | 31.81M |
| Total Liabilities | 10.07M | 6.31M | 4.21M | 2.77M | 33.44M |
| Stockholders Equity | 770.49M | 145.82M | 90.43M | 41.50M | -15.09M |
Cash Flow | |||||
| Free Cash Flow | -37.17M | -29.39M | -29.90M | -11.85M | -7.55M |
| Operating Cash Flow | -36.99M | -29.23M | -29.84M | -11.46M | -7.47M |
| Investing Cash Flow | -305.11M | -110.57M | -63.00K | -394.00K | -56.00K |
| Financing Cash Flow | 663.23M | 83.59M | 75.96M | 36.96M | -583.00K |
Belite Bio, Inc. ADR Technical Analysis
Neutral
165.45
Price Trends
155.86
Negative
163.21
Negative
134.91
Positive
Market Momentum
-4.20
Negative
45.60
Neutral
54.57
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BLTE, the sentiment is Neutral. The current price of 165.45 is above the 20-day moving average (MA) of 144.98, above the 50-day MA of 155.86, and above the 200-day MA of 134.91, indicating a neutral trend. The MACD of -4.20 indicates Negative momentum. The RSI at 45.60 is Neutral, neither overbought nor oversold. The STOCH value of 54.57 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for BLTE.
Belite Bio, Inc. ADR Risk Analysis
Belite Bio, Inc. ADR disclosed 111 risk factors in its most recent earnings report. Belite Bio, Inc. ADR reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 2 New Risks
1.
We no longer qualify as an "emerging growth company" and, as a result, we are no longer able to avail ourselves of certain reduced reporting requirements applicable to emerging growth companies. Q4, 2025
2.
We will rely on third parties to manufacture clinical and commercial supplies of tinlarebant and other product candidates and future products. Q4, 2025
Belite Bio, Inc. ADR Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | $1.91B | 12.79 | 17.19% | ― | 20.71% | -5.53% | |
71 Outperform | $3.79B | 50.71 | 13.26% | ― | 56.71% | ― | |
58 Neutral | $3.38B | -46.68 | -5.89% | ― | 157.97% | 86.11% | |
58 Neutral | $6.16B | -24.27 | -60.37% | ― | -100.00% | 1.57% | |
57 Neutral | $5.79B | -63.31 | -26.70% | ― | ― | -85.65% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $3.20B | -7.17 | -52.20% | ― | ― | -7.88% |
* Healthcare Sector Average
BLTE
Belite Bio, Inc. ADR
143.35
83.67
140.20%
DNLI
Denali Therapeutics
19.52
4.82
32.79%
KNSA
Kiniksa Pharmaceuticals
48.42
18.19
60.17%
BEAM
Beam Therapeutics
29.40
10.82
58.23%
HRMY
Harmony Biosciences Holdings
32.20
-3.40
-9.55%
CNTA
Centessa Pharmaceuticals
39.62
27.70
232.38%
Belite Bio, Inc. ADR Corporate Events
Belite Bio Kicks Off Tinlarebant NDA and Ramps Up Commercial Build-Out on Strong Cash Base
May 20, 2026
On May 20, 2026, Belite Bio reported unaudited results for the quarter ended March 31, 2026, alongside a broad corporate update that underscores its transition toward commercialization. The company has begun a rolling U.S. NDA submission for tinla...
Belite Bio Starts FDA Rolling NDA for Tinlarebant in Stargardt Disease
Apr 21, 2026
On April 21, 2026, Belite Bio, Inc. announced it had begun a rolling submission of a New Drug Application to the U.S. Food and Drug Administration for tinlarebant, an oral therapy for Stargardt disease type 1 that has received Breakthrough Therapy...
Belite Bio Posts 2025 Form 20-F Annual Report Online as Late-Stage Retinal Drug Trials Advance
Mar 31, 2026
Belite Bio, Inc., a clinical-stage developer of treatments for degenerative retinal diseases such as Stargardt disease type 1 and geographic atrophy in dry age-related macular degeneration, has advanced its lead oral candidate tinlarebant through ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.